Determination of the amino acid sequence of bovine parathyroid hormone has led to the synthesis of a tetratriacontapeptide corresponding to the aminoterminal 1-34 residues of the native molecule. The specific biological effects of this synthetic peptide on bone and kidney are qualitatively identical to those of the native hormone in classical bioassays in vivo and in several systems in vitro. Potency of the synthetic peptide equals or exceeds that of a biologically active fragment of comparable size isolated from the native hormone; the synthetic and natural peptides show complete immunological crossreactivity. Thus, essential requirements for the physiological actions of the peptide on both skeletal and renal tissue are contained within the 34 amino-terminal amino acids. The potency of the synthetic peptide, relative to that of the native (84-amino acid) polypeptide, is greater in vitro than in vivo; this suggests that the carboxyl terminal two-thirds of the native hormone may protect the circulating polypeptide from rapid metabolic degradation.
Recently, the amino acid sequence of the major form of bovine parathyroid hormone has been determined (1-7) (Fig. 1) . During these studies, attention has been directed particularly to the amino terminal portion of the polypeptide, since our earlier work (6) indicated that a biologically active fragment could be prepared from the amino terminus of the bovine molecule by hydrolysis in dilute acid (Keutmann, et al., manuscript in preparation). Characteristically, dilute acid hydrolysis causes cleavage at aspartate residues in polypeptide chains (6) . Since aspartate is not found within the first 30 amino-terminal residues (2, 4) , it seemed likely that this portion of the sequence contained the biologically active region of the hormone.
We now report (1) synthesis by a solid-phase method (8) of the tetratriacontapeptide consisting of residues 1-34; the synthetic peptide is highly active in vivo and in vitro on renal and skeletal tissue. This result confirms our structure for the amino terminus of the hormone, and also that a limited portion of the total molecule is indeed sufficient for expression of the action of the hormone on both physiological receptors, kidney and bone.
MATERIALS AND METHODS Chemical
Improved solid-phase supports incorporating unique advantages offered by graft copolymerization (9, 10) have been developed for use in peptide synthesis and will be described in detail elsewhere. The peptide chain was assembled by the stepwise addition of protected amino acids to an active site at the surface of the polymer support using the procedure described by Merrifield (8, 12) .
Poly(trifluorochloroethylene-g-chloromethyl styrene) containing 7.14% polystyrene and 0.20 mmol CH2Cl/g was used as the solid support (9, 10). The synthesis was commenced with 9.910 g (0.60 millimole) of resin-esterified phenylalanine. The Na-tertiary butyloxycarbonyl (Boc) group was used to protect the a-amino function. In addition, the carboxyl side chains of aspartic and glutamic acids were blocked as their benzyl esters, the serine hydroxyls as their benzyl ethers, and the guanidine function of arginine as its nitro derivative. The imidazole nitrogen on histidine was blocked with the dinitrophenyl group and the e-amino group of lysine with the trifluoroacetyl group.
Deprotection of the Boc group was achieved with 4 M HCl in dioxane, except in the case of glutamine where tri- fluoroacetic acid was used to minimize the possibility of pyroglutamyl chain termination (17) . At the tryptophan and all following amino acid addition steps, 1% mercaptoethanol was added to the 4 M HCl-dioxane reagent, and to subsequent dioxane washes, to minimize oxidation of the labile tryptophan residue (18) .
The individual amino acids were coupled with dicyclohexylcarbodiimide except in the case of glutamine and asparagine (15) where the modified p-nitrophenol active ester method (16) was employed. The completeness of reaction after each coupling step was monitored by the ninhydrin procedure (13) . In the event that a positive ninhydrin test was found, the coupling reaction was prolonged or repeated or the unreacted amino groups were acetylated (14) .
Quantities of peptide-resin (about 2 g) were removed from the reaction mixture after steps 25, 19, 14, and 2 to enable sequences 25-34, 19-34, 14-34, and 2-34 to be prepared. Similarly synthesis starting with resin-esterified lysine gave the 1-13 fragment.
At the completion of the stepwise amino acid additions, the dinitrophenyl groups on the histidine residues were removed by treatment of the peptide-resin with thiophenol (19) . The peptide was cleaved from the resin and, simultaneously, the benzyl and nitro protecting groups of aspartic acid, glutamic acid, serine, and arginine were removed with hydrogen fluoride in the presence of anisole. The crude peptide so obtained (320 mg, 0.073 mmol) was then further treated with 1 M piperidine in 8 M urea (20) to remove the trifluoroacetyl groups from the lysine residues. Gel filtration was used as a preliminary purification procedure, followed by chromatography on carboxymethyl cellulose (11) .
Amino acid composition of natural and synthetic peptides was determined by combined acid-and enzymic-hydrolysis techniques and automatic amino acid analysis as previously described (21) . Preparation of peptide subfragments, and determination of amino acid sequence utilizing the phenylisothiocyanate technique by manual and automatic procedures were performed by previously reported approaches (6, (21) (22) (23) . Radioimmunoassay, using GP-1 antiserum, was performed as described (24) .
Biological
Biological properties of the synthetic hormone were evaluated by the following methods, highly specific for parathyroid hormone: bioassay in rats based on increase in serum calcium (25) and the rapidly-induced rise in urinary excretion of phosphate and 3': 5'-cyclic AMP (A>p; ref 26); bioassay in vitro was based on activation of renal adenyl cyclase (27) and increase in A>p in fetal-rat calvaria (28) .
All the structural and synthetic studies in the present report are concerned with the major hormonal polypeptide isolated from extracts of pooled bovine parathyroid glands (1-3). Several additional chemically distinct, biologicallyactive forms of the bovine hormone have also been isolated during purification studies (1, 3) .
RESULTS
The crude peptide (overall yield 73%), after removal of trifluoroacetyl blocking groups and initial purification by gel filtration, was further fractionated by chromatography on CM-cellulose. The active peptide eluted at a conductance and pH characteristic of that for active fragments of the Proc. Nat Acad. Sci. USA Biological tests on the purified synthetic peptide gave the following results. Eleven separate bioassays in vitro showed potency ranging from 400 to 600 USP units/mg. Repeated assays of the native hormonal molecule in vitro had shown an activity of 1600 units/mg. The active fragment hydrolyzed from the native molecule was tested within the same series of assays; it showed a biological activity of 320 units/mg. Separate assays showed that successive exposure of the native molecule to HF and piperidine, as was applied to the synthetic product, causes significant reduction of biological activity. A representative bioassay of the synthetic product in vitro with renal adenyl cyclase is shown in Fig. 2 ; the response was Fig. 3B , illustrating a bioassay against the standard natural product. A further biological test was performed by injecting the product intravenously into parathyroidectomized rats and determining A>p and phosphate in the urine (Fig. 4) . The response was qualitatively identical to that characteristic of the native hormone (26) . Tests of the immunological activity of synthetic product and natural fragments of corresponding size indicated an identical response in the radioimmunoassay. Results are plotted (Fig. 5) synthesized. Recent (3) studies have shown that the specific biological effects of the hormone on bone and kidney are properties common to a single hormonal molecule purified from bovine parathyroid glands. Further investigations (26) (27) (28) have shown that the earliest effect of parathyroid hormone in each receptor tissue is specific activation of adenyl cyclase and a consequent rise in the intracellular concentration ofA>p within each tissue. These biochemical effects of the hormone provide further specific criteria in addition to classical bioassay methods for evaluation of synthetic products. The tetratriacontapeptide described in this report shows all of these specific properties of the native molecule; the synthetic peptide stimulates adenyl cyclase in both bone and kidney cells, elevates blood calcium in rats and dogs, and causes an increase in renal excretion of both cyclic AMP and phosphate in the rat. Thus, it is clear that hormonal effects on both kidney and bone are the expression of the same limited region of the hormone molecule, a sequence of 34 amino acids or less at the amino terminus. Recent studies with fragments of the native molecule indicate that the sequence 1-29 is, in fact, sufficient for biological activity. (Keutmann et al., manuscript in preparation).
Study of the relative potency of the synthetic product, native hormone, and biologically active fragments of the native hormone that correspond in size to the synthetic tetratriacontapeptide indicate that the synthetic product is, if anything, more active in vitro than the natural fragments, and has one-quarter to one-third of the potency of native hormone. The latter comparison does not take into consideration the finding that exposure of the native hormone to HF and piperidine results in significant loss of biological activity. Hence, it seems possible that the activity of the synthetic product may, in fact, closely approximate that of the native, 84-amino acid, peptide in vitro. Comparison of the potency of the synthetic fragment and the native hormone in the rat bioassay suggests that the synthetic fragment may be relatively less active in vivo than in vitro. If confirmed, this finding may point to the biological role of the carboxylterminal two-thirds of the structure of the native, 84-amino acid peptide. The carboxyl-terminal portion of the molecule may protect the hormone from metabolic degradation; it will be of interest to determine if the synthetic fragment is cleared more rapidly from blood than the native hormone.
However, in the study of essential details of structureactivity relations in parathyroid hormone, attention may now be focused on the amino terminal portion. Detailed study of this region should result in a definition of the minimum structure required for renal or osseous biological activity and resolution of the question as to whether receptor-binding requirements are identical in kidney and bone cells. We have shown that the peptide consisting of residues 1-13 is devoid of biological activity; hence, some portion of the sequence 14-34 is absolutely required for activity. We have already prepared four additional peptides, representing the sequences 2-34, 14-34, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] , and 25-34, respectively; biological tests of these peptides are in progress. It will be important to synthesize and test additional peptides that are shortened by successive deletion of amino acids from either the amino or carboxyl end of the 1-34 sequence. Analogues of the sequence will also be of interest to evaluate; choices for substitution will be guided by the comparative structural studies now in progress concerning the other bovine hormone molecules and the porcine hormone. In work already presented in a preliminary report (1) , we have demonstrated that in the closely similar sequence of the porcine peptide some changes are found within the region of the active fragment sequence; leucine is substituted for phenylalanine at position six and the single methionine residue of the porcine hormone is located at position eight rather than position eighteen.
Several interesting conclusions could be drawn from tests of the immunological reactivity of fragments of the native hormone, the synthetic tetratriacontapeptide, and native hormone in our standard immunoassay system employing the GP-1 antiserum used in clinical studies (1, 4) .
The identical reactivity of the natural fragments and the synthetic product provided additional validation of the chemical identity of the synthetic tetratriacontapeptide with the sequence 1-34 of the native hormone. However, the finding that neither natural nor synthetic fragments displaced more than 50% of labeled intact bovine hormone from antibody indicates that, at least at the dilutions of antiserum used, antibodies must be present that recognize portions of the sequence outside of the 1-34 region. Recent findings in several laboratories (1, 30, 31) 
